What Sparsentan's FDA Approval Means for Rare Kidney Disease

On April 13, 2026, the FDA granted full approval to Filspari (sparsentan) for reducing proteinuria in adults and pediatric patients aged 8 and older with focal segmental glomerulosclerosis who do not have nephrotic syndrome.1 Developed by Travere Therapeutics, sparsentan is the first and only FDA-approved medicine for FSGS, marking a regulatory milestone in a disease area that has historically relied on off-label treatment strategies.

The approval is a case study in navigating regulatory pathways for rare, heterogeneous kidney diseases.1 The label aligns with KDIGO clinical practice guidelines for managing FSGS patients, which emphasize proteinuria reduction as a primary strategy for slowing disease progression.

Nephrotic syndrome is defined by the concurrent presence of proteinuria greater than 3.5 g/24h, edema, and albumin below 3.0 g/dL.1 The approved indication specifically targets patients without this constellation of findings, a population Travere estimates at more than 30,000 individuals in the United States. Combined with sparsentan's existing indication for IgA nephropathy, the total addressable population now exceeds 100,000 patients in the U.S.

"Today marks a historic milestone for people living with FSGS, who for the first time have an FDA-approved medicine for this rare and devastating condition," said Eric Dube, PhD, president and chief executive officer, Travere Therapeutics, in a press release.1 "This approval reflects years of perseverance and our belief that those living with FSGS deserve better."

FSGS is a progressive scarring disorder of the kidney's glomeruli that can lead to kidney failure.1 In patients without nephrotic syndrome, the condition is driven largely by mechanical stress on the glomeruli and the activation of inflammatory and fibrotic pathways. The disease spans all categories of FSGS, and the lack of any previously approved therapy made this a high-unmet-need indication from a regulatory strategy perspective.

What Does the Phase III Evidence Look Like?

The approval was supported by data from the Phase III DUPLEX study, the largest interventional trial conducted to date in FSGS, enrolling 371 patients between ages 8 and 75 with biopsy-proven or genetic disease.1 The global, randomized, double-blind, active-controlled trial compared sparsentan at 800 mg against maximum labeled dose irbesartan at 300 mg, with a primary endpoint measuring the rate of change in estimated glomerular filtration rate from baseline to Week 108.

In the overall study population, patients on sparsentan experienced a 46% reduction in proteinuria from baseline to Week 108, compared to 30% for irbesartan.1 In the subgroup without nephrotic syndrome, the population reflected in the new indication, sparsentan produced a 48% reduction versus 27% for irbesartan.

From a manufacturing and formulation standpoint, the compound's dual mechanism, targeting both endothelin A and angiotensin II receptors, presents the kind of pharmacological complexity that requires careful dose-titration protocols.1 The safety profile was generally consistent with irbesartan across both adult and pediatric patients. The most common adverse reactions in FSGS patients occurring in at least 5% of patients include peripheral edema, hypotension, hyperkalemia, dizziness, and anemia.

Kirk Campbell, M.D., president, National Kidney Foundation, stated in the press release,1"For decades, treatment options have been limited, often relying on off-label therapies such as long-term steroids that can carry a significant burden for patients. In the DUPLEX Study, FILSPARI delivered rapid and sustained reductions in proteinuria compared to irbesartan, with particularly meaningful effects in patients without nephrotic syndrome."

"The approval of FILSPARI as the first medication for people with FSGS is a life-changing moment for patients and families who have waited far too long," said Josh Tarnoff, chief executive officer, NephCure, in the press release.1 "This milestone reflects the strength and perseverance of an extraordinary collective and broad stakeholder community who participated in research, raised awareness and never gave up hope."

How Did the FDA Characterize Its Approval for Sparsentan?

The FDA's own characterization of the approval emphasizes that full approval, not accelerated approval, was granted on the basis of a randomized trial demonstrating significant proteinuria improvement in patients without nephrotic syndrome compared to standard of care.2

Tracy Høeg, MD, PhD, acting director, the Center for Drug Evaluation and Research, stated in a press release,2 "FDA reviewers concluded that Filspari's effect on proteinuria in this FSGS subpopulation had a high likelihood of translating into clinically meaningful benefit of slowing the loss of kidney function and progression to kidney failure."

That evidentiary standard, surrogate endpoint data considered sufficient to predict clinical benefit, reflects a regulatory posture for sponsors designing pivotal trials in rare kidney diseases.2 Sparsentan held orphan-drug designation as well, granted in 2015, underscoring the long development timeline common to rare disease therapeutics.

References

1. Travere Therapeutics, Inc. Travere Therapeutics Announces Full FDA Approval of FILSPARI (sparsentan), the First and Only Approved Medicine for FSGS. Press release. April 13, 2026. https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Announces-Full-FDA-Approval-of-FILSPARI-sparsentan-the-First-and-Only-Approved-Medicine-for-FSGS/default.aspx
2. First Food and Drug Administration-approved treatment for patients with focal segmental glomerulosclerosis, a rare kidney condition. U.S. Food and Drug Administration. Published April 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/first-fda-approved-treatment-patients-focal-segmental-glomerulosclerosis-rare-kidney-condition